Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits

British Journal of Pharmacology

Volumn 164, Issue 1, 2011, Pages 119-131

  Iwasa, Masamitsu ^a   Yamada, Yoshihisa ^a   Kobayashi, Hiroyuki ^a   Yasuda, Shinji ^a   Kawamura, Itta ^a   Sumi, Shohei ^a   Shiraki, Takeru ^a   Yamaki, Takahiko ^a   Ushikoshi, Hiroaki ^a   Hattori, Arihiro ^a   Aoyama, Takuma ^a   Nishigaki, Kazuhiko ^a   Takemura, Genzou ^a   Fujiwara, Hisayoshi ^a   Minatoguchi, Shinya ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; GLP 1 receptor; miglitol; myocardial infarction; PI3 kinase; plasma GLP 1 level

Indexed keywords

EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; MIGLITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; GLUCAGON LIKE PEPTIDE 1 BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCOGENOLYSIS; HEART EJECTION FRACTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INSULIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; REPERFUSION INJURY; UPREGULATION; WESTERN BLOTTING;

1-DEOXYNOJIRIMYCIN; ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; DRUG SYNERGISM; GLUCAGON-LIKE PEPTIDE 1; GLYCOGENOLYSIS; HEART; HEART RATE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PEPTIDE FRAGMENTS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; RECEPTORS, GLUCAGON;

EID: 79961231117     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01357.x     Document Type: Article

References (35)

1. Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H, et al,. (2008). Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 57: 1299-1306.
2. Ban K, Noyan-Ashraf M, Hoefer J, Bolz SS, Drucker DJ, Husain M, (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340-2350. (Pubitemid 351653542)
3. Barragan JM, Rodriguez RE, Blazquez E, (1994). Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol Endocrinol Metab 266: E459-E466.
4. Bischoff H, (1994). Pharmacology of α-glucosidase inhibition. Eur J Clin Invest 24 (Suppl. 3): 3-10.
5. Bojanowska E, Stempniak B, (2002). Effects of glucagon-like peptide-1(7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat. J Endocrinol 172: 303-310. (Pubitemid 34183079)
6. Bollen M, Stalmans W, (1989). The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the α-1,6-glucosidase activity of the debranching enzyme. Eur J Biochem 181: 775-780. (Pubitemid 19146948)
7. Bollen M, Vandebroeck A, Stalmans W, (1988). Deoxynojirimycin and related compounds inhibits glycogenolysis in the liver without affecting the concentration of phosphorylase a. Biochem Pharmacol 37: 905-909. (Pubitemid 18058463)
8. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM, (2005). Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151. (Pubitemid 40105106)
9. Buteau J, Roduit R, Susini S, Prentki M, (1999). Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42: 856-864. (Pubitemid 29325077)
10. Deacon CF, (2004). Circulation and degradation of GIP and GLP-1. Horm Metab Res 36: 761-765. (Pubitemid 40115896)
11. Drucker DJ, (2006). The biology of incretin hormones. Cell Metab 3: 153-165.
12. Grieve DJ, Cassidy RS, Green BD, (2009). Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157: 1340-1351.
13. Guerrant GO, Moss CW, (1984). Determination of monosaccharides as aldononitrile, o-methyloxime, alditol, and cyclitol acetate derivatives by gas chromatography. Anal Chem 56: 633-638. (Pubitemid 14568630)
14. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM, (2005). Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976. (Pubitemid 40139686)
15. Hira T, Mochida T, Miyashita K, Hara H, (2009). GLP-1 secretion is enhanced directly in the ileum, but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate in rats. Am J Physiol Gastrointest Liver Physiol 297: G663-G671.
16. Iwasa M, Kobayashi H, Yasuda S, Kawamura I, Sumi S, Yamada Y, et al,. (2010). Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagons-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol 55: 625-634.
17. Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, et al,. (2003). Glucagon-like peptide-1(7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 24: 569-578. (Pubitemid 36829346)
18. Knudsen LB, Pridal L, (1996). Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318: 429-435. (Pubitemid 27046288)
19. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE, (2002). The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4: 329-335. (Pubitemid 34947095)
20. Minatoguchi S, Arai M, Uno Y, Kariya T, Nishida Y, Hashimoto K, et al,. (1999). A novel anti-diabetic drug, miglitol, markedly reduces myocardial infarct size in rabbits. Br J Pharmacol 128: 1667-1672. (Pubitemid 30011879)
21. Moritoh Y, Takeuchi K, Hazama M, (2009). Chronic administration of voglibose, an α-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. J Pharmacol Exp Ther 329: 669-676.
22. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al,. (2009). GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983.
23. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ, (1994). Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539. (Pubitemid 24096293)
24. Ossum A, van Deurs U, Engstrom T, Jensen JS, Treiman M, (2009). The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 60: 411-417.
25. Pagano G, Marena S, Corgiat-Mansin L, Cravero F, Giorda C, Bozza M, et al,. (1995). Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diabete Metab 21: 162-167.
26. Satoh N, Shimatsu A, Yamada K, Aizawa-Abe M, Suganami T, Kuzuya H, et al,. (2000). An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients. Metabolism 55: 786-793.
27. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP, (2006). Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699. (Pubitemid 44881367)
28. Sonne DP, Engstrom T, Treiman M, (2008). Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146: 243-249.
29. Stamler J, Vaccaro O, Neaton JD, Wentworth D, (1993). Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16: 434-444. (Pubitemid 23046633)
30. Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L, (2004). Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 1: 40-43.
31. Timmers L, Henriques JPS, de Kleijin DPV, DeVries JH, Kemperman H, Steendijk P, et al,. (2009). Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510.
32. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A, (1999). Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22: 920-924. (Pubitemid 29241045)
33. UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 352: 854-865.
34. Wang N, Minatoguchi S, Chen X, Uno Y, Arai M, Lu C, et al,. (2004). Antidiabetic drug miglitol inhibits myocardial apoptosis involving decreased hydroxyl radical production and Bax expression in an ischaemia/reperfusion rabbit heart. Br J Pharmacol 142: 983-990. (Pubitemid 39037048)
35. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al,. (2002). Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110: 43-52. (Pubitemid 34743464)